Brand Name | Status | Last Update |
---|---|---|
vabomere | New Drug Application | 2024-12-12 |
Expiration | Code | ||
---|---|---|---|
MEROPENEM / VABORBACTAM, VABOMERE, REMPEX | |||
2027-08-29 | GAIN | ||
2022-08-29 | NCE |
Code | Description |
---|---|
J2186 | Injection, meropenem and vaborbactam, 10mg/10mg (20mg) |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | — | — | — | 1 |
Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 1 | — | — | — | 1 |
Drug common name | Vaborbactam |
INN | vaborbactam |
Description | Vaborbactam (INN) is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.
... More |
Classification | Small molecule |
Drug class | beta-lactamase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1 |
PDB | — |
CAS-ID | 1360457-46-0 |
RxCUI | — |
ChEMBL ID | CHEMBL3317857 |
ChEBI ID | — |
PubChem CID | 56649692 |
DrugBank | DB12107 |
UNII ID | 1C75676F8V (ChemIDplus, GSRS) |